Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression
Authors' conclusion
Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual-agonist therapy for obese patients.
Study context
- Population
- Individuals with obesity
- Participants
- 3,545 individuals3 RCTs
- Comparison
- Cagrisema or cagrilintide vs semaglutide
- Outcome
- Weight loss
Methodological detailsmeta-regression, random-effects model
- Meta-regression
- Random-effects model
Pooled result
As reported in the abstract
Cagrisema vs SemaglutideMD, % (95% CI)P value
Percentage change in body weight; greater weight loss with Cagrisema
−7.47(−10.58 to −4.36)
P < 0.001Cagrisema vs SemaglutideMD, kg (95% CI)P value
Absolute change in body weight; greater weight loss with Cagrisema
−7.60(−10.33 to −4.86)
P < 0.001Further pooled results
| Outcome | MD (mmol/L) (95% CI) | P value | |
|---|---|---|---|
| Lipid parametersCagrisemavs SemaglutideLDL-C modestly higher with combination therapy | 0.29 (0.02–0.55) | P = 0.03 | |
| −0.500.51Difference, mmol/L (linear scale) |
Lipid parameters
- Lipid parameters mostly similar between groups
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| Adverse events, Cagrisema vs semaglutideCagrisemavs SemaglutideAdministration-site conditions | 3.27 (1.27–8.46) | |
| Adverse events, Cagrisema vs semaglutideCagrisemavs SemaglutideNausea | 1.64 (1.01–2.66) | |
| Serious adverse events, Cagrilintidevs semaglutideHigher risk with cagrilintide monotherapy | 1.83 (1.03–3.24) | |
| 0.10.31310Relative risk (log scale) |
Adverse events, Cagrisema vs semaglutide
- Overall and serious AEs comparable between cagrisema and semaglutide
Original publication
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti‐Obesity Medications: A Systematic Review, Meta‐Analysis and Meta‐Regression. Diabetes Obes Metab. Published 16 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →